HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial.

AbstractBACKGROUND:
Hepatic grafr-versus-host disease (GVHD) is associated with significant morbidity and mortality. Standard therapy includes systemically administered immunosuppressive drugs. More recent reports have described catheter-directed intrahepatic arterial (IHA) delivery of low-dose methotrexate (MTX) and methylprednisolone in the treatment of corticosteroid-resistant severe hepatic GVHD.
OBJECTIVE:
This article reports on MTX toxicity and the variability in plasma drug concentrations after IHA administration of low-dose MTX in patients with severe hepatic GVHD.
METHODS:
In this open-label, uncontrolled pilot study, MTX and methylprednisolone were administered via the hepatic artery in patients with corticosteroid-resistant grade III or IV GVHD of the liver. Patients also received standard therapy. MTX concentrations were measured in the hepatic artery 5 and 10 minutes after injection and in peripheral venous blood at 1, 2, and 24 hours.
RESULTS:
Six patients (5 males [83.3%], I female [16.7%]; median age, 32 years; range, 8-42 years) were enrolled in the study. No hepatotoxicity was observed after IHA administration of MTX. In 5 patients with normal renal function, plasma drug concentrations 24 hours after administration of MTX ranged from 0.01 to 0.12 micromol/L (mean [SD], 0.043 [0.042] micromol/L). In 1 patient with renal failure, plasma MTX concentrations were 1.0 micromol/L 24 hours after administration and 0.07 micromol/L 5 days after administration. The severe hematologic and renal toxicity observed in this patient may have contributed to his death. Adverse events in patients with GVHD and normal renal function, who had normal plasma MTX concentrations, were comparable to those that have been reported after administration of an intravenous infusion.
CONCLUSIONS:
In patients with GVHD and normal renal function, IHA administration of low-dose MTX was not associated with liver or bone marrow toxicity. Further study is needed to determine the optimal protocols for treating corticosteroid-resistant hepatic GVHD.
AuthorsAllan I Bloom, Michael Y Shapira, Reuven Or, Talia Sasson, Igor B Resnick, Irena Zilberman, Anthony Verstandig, Memet Aker, Shimon Slavin, Mordechai Muszkat
JournalClinical therapeutics (Clin Ther) Vol. 26 Issue 3 Pg. 407-14 (Mar 2004) ISSN: 0149-2918 [Print] United States
PMID15110133 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Methylprednisolone
  • Methotrexate
Topics
  • Adolescent
  • Adult
  • Child
  • Drug Resistance
  • Female
  • Graft vs Host Disease (drug therapy)
  • Hepatic Artery
  • Humans
  • Immunosuppressive Agents (administration & dosage, adverse effects, therapeutic use)
  • Infusions, Intra-Arterial
  • Male
  • Methotrexate (administration & dosage, adverse effects, therapeutic use)
  • Methylprednisolone (therapeutic use)
  • Renal Insufficiency (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: